image
Healthcare - Biotechnology - NASDAQ - CN
$ 37.64
1.27 %
$ 4.13 B
Market Cap
-14.62
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ZLAB stock under the worst case scenario is HIDDEN Compared to the current market price of 37.6 USD, Zai Lab Limited is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ZLAB stock under the base case scenario is HIDDEN Compared to the current market price of 37.6 USD, Zai Lab Limited is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ZLAB stock under the best case scenario is HIDDEN Compared to the current market price of 37.6 USD, Zai Lab Limited is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ZLAB

image
$40.0$40.0$38.0$38.0$36.0$36.0$34.0$34.0$32.0$32.0$30.0$30.0$28.0$28.0$26.0$26.0$24.0$24.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
399 M REVENUE
49.59%
-282 M OPERATING INCOME
23.04%
-257 M NET INCOME
23.17%
-215 M OPERATING CASH FLOW
-8.42%
-375 M INVESTING CASH FLOW
-3381.75%
350 M FINANCING CASH FLOW
5538.97%
106 M REVENUE
-2.37%
-56.3 M OPERATING INCOME
17.06%
-48.4 M NET INCOME
40.70%
-61.7 M OPERATING CASH FLOW
-10.63%
326 M INVESTING CASH FLOW
193.78%
43.1 M FINANCING CASH FLOW
-81.86%
Balance Sheet Zai Lab Limited
image
Current Assets 1.05 B
Cash & Short-Term Investments 780 M
Receivables 89.4 M
Other Current Assets 181 M
Non-Current Assets 135 M
Long-Term Investments 3.12 M
PP&E 69.5 M
Other Non-Current Assets 62.7 M
65.75 %7.54 %15.30 %5.86 %5.29 %Total Assets$1.2b
Current Liabilities 299 M
Accounts Payable 101 M
Short-Term Debt 140 M
Other Current Liabilities 58.7 M
Non-Current Liabilities 45.5 M
Long-Term Debt 13.7 M
Other Non-Current Liabilities 31.8 M
29.26 %40.53 %17.03 %3.98 %9.21 %Total Liabilities$344.9m
EFFICIENCY
Earnings Waterfall Zai Lab Limited
image
Revenue 399 M
Cost Of Revenue 148 M
Gross Profit 251 M
Operating Expenses 533 M
Operating Income -282 M
Other Expenses -25 M
Net Income -257 M
400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)399m(148m)251m(533m)(282m)25m(257m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
62.94% GROSS MARGIN
62.94%
-70.71% OPERATING MARGIN
-70.71%
-64.44% NET MARGIN
-64.44%
-30.57% ROE
-30.57%
-21.68% ROA
-21.68%
-27.49% ROIC
-27.49%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Zai Lab Limited
image
00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -257 M
Depreciation & Amortization 11.9 M
Capital Expenditures -5.66 M
Stock-Based Compensation 70.7 M
Change in Working Capital -68.4 M
Others -15.4 M
Free Cash Flow -276 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Zai Lab Limited
image
Wall Street analysts predict an average 1-year price target for ZLAB of $62.2 , with forecasts ranging from a low of $50 to a high of $101 .
ZLAB Lowest Price Target Wall Street Target
50 USD 32.84%
ZLAB Average Price Target Wall Street Target
62.2 USD 65.25%
ZLAB Highest Price Target Wall Street Target
101 USD 168.33%
Price
Max Price Target
Min Price Target
Average Price Target
110110100100909080807070606050504040303020201010Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Zai Lab Limited
image
Sold
0-3 MONTHS
8.45 M USD 6
3-6 MONTHS
4.52 M USD 4
6-9 MONTHS
12.8 K USD 1
9-12 MONTHS
1.34 M USD 9
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating zocilurtatug pelitecan, or ZL-1310, the Company's potential first-in-class, Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for patients with extensive-stage small cell lung cancer (ES-SCLC), will be presented today during a poster session at the 2025 American Society of Clinical Oncology (AS. businesswire.com - 2 weeks ago
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology. “The data presented today from the PANOVA-3 trial of Tumor Treating. businesswire.com - 2 weeks ago
Zai Lab Announces Participation in Investor Conferences in June 2025 SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in June 2025: Jefferies Global Healthcare Conference Fireside Chat: Wednesday, June 4, 2025, 10:30 a.m. EST Webcast Link: https://wsw.com/webcast/jeff319/zlab/1845848 Location: New York, NY Goldman Sachs 46th Annual Healthcare Conference Time: Monday, June 9, 2025 Location: Miami, FL S. businesswire.com - 2 weeks ago
Zai Lab Limited Is Well Positioned For Long-Term Growth Zai Lab leverages partnerships and regulatory expertise to commercialize innovative drugs in China, reducing trial risks and accelerating market entry. A robust pipeline with multiple anticipated product launches each year, driving strong revenue growth toward a $1.5–$2 billion target by 2028. The company's strong balance sheet and diverse product portfolio minimize risk. seekingalpha.com - 2 weeks ago
Zai Lab Limited: Banking On Chinese Pharma Growth Zai Lab Limited has shown positive momentum since my last update, signaling a more optimistic outlook for the company. ZLAB received Fast Track designation from the U.S. FDA, highlighting progress in its pipeline and regulatory milestones. Recent quarterly earnings provide insight into ZLAB's financial health, supporting the investment thesis of ongoing growth potential. seekingalpha.com - 3 weeks ago
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZL-1310, the Company's potential first-in-class Delta-like ligand (DLL3) antibody-drug conjugate (ADC), for the treatment of extensive-stage small cell lung cancer (ES-SCLC). ZL-1310, which is being evaluated in an ongoing global Phase 1a/1b clinical trial (NCT06179069), previously received an Orphan Drug desig. businesswire.com - 4 weeks ago
Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript Zai Lab Limited (NASDAQ:ZLAB ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado - President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Jonathan Wang - Chief Business Officer Conference Call Participants Michael Yee - Jefferies Louise Chen - Scotiabank Yen-Der Li - Leerink Partners Li Watsek - Cantor Yigal Nochomovitz - Citi Anupam Rama - JPMorgan Jack Lin - Morgan Stanley Rebecca Liang - Bernstein Linhai Zhao - Goldman Sachs Operator Hello, ladies and gentlemen, thank you for standing by, and welcome to Zai Lab's First Quarter 2025 Financial Results Conference Call. At this time, all participants are in listen-only mode. seekingalpha.com - 1 month ago
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 month ago
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2025, along with recent product highlights and corporate updates. “In the first quarter, we continued to advance both our global pipeline and commercial business,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “We are rapidly expanding our global portfolio, having recently presented promising data for two next-generation oncology t. businesswire.com - 1 month ago
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025 SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, next-generation, investigational oncology therapies that it has global rights to, ZL-6201, a novel leucine-rich repeat-containing protein 15 (LRRC15) antibody-drug conjugate (ADC) targeting multiple solid tumors, and ZL-1222, an innovative anti-PD-1/ interleukin-12 (IL-12) immunocytokine for cancer immunotherapy, during poster se. businesswire.com - 1 month ago
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The application is intended for patients whose disease is locally advanced or metastatic, or where surgical resection is likely to. businesswire.com - 1 month ago
All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy Zai Lab Limited (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 2 months ago
8. Profile Summary

Zai Lab Limited ZLAB

image
COUNTRY CN
INDUSTRY Biotechnology
MARKET CAP $ 4.13 B
Dividend Yield 0.00%
Description Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Contact Jinchuang Plaza, Shanghai, 201210 https://www.zailaboratory.com
IPO Date Sept. 20, 2017
Employees 1869
Officers Dr. Rafael G. Amado M.D. President and Head of Global Research & Development Mr. Tong Zhu Chief Commercial Officer of Greater China Dr. Yajing Chen Ph.D. Chief Financial Officer Mr. Frazor Titus Edmondson III, J.D. Chief Legal Officer & Joint Corporate Secretary Dr. Robert J. Brown M.D. Chief Medical Officer of Oncology Ms. Christine Chiou Senior Vice President & Head of Investor Relations Dr. Jonathan J. Wang MBA, Ph.D. Chief Business Officer Dr. James Yan DABT, M.D., Ph.D. Chief Operating Officer of R&D Mr. Joshua L. Smiley President & Chief Operating Officer Dr. Ying Du Ph.D. Founder, Chairperson & Chief Executive Officer